Evidence map›Paper›PMID 26098859›Full record

ArticleOncotarget2015

Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma.

Reham Abdel-Wahab, Samir Shehata, Manal M Hassan, Lianchun Xiao, Ju-Seog Lee, Sheree Cheung, Hoda H Essa, Hesham M Hassabo, Ahmed S Shalaby, Eman Mosad and 6 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Insulin-Like Growth Factor (IGF) System in Liver Diseases.International journal of molecular sciences · 2018
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Reham Abdel-WahabDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Samir ShehataDepartment of Clinical Oncology, Assiut University, Assiut, Egypt.
Manal M HassanDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lianchun XiaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ju-Seog LeeDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sheree CheungDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hoda H EssaDepartment of Clinical Oncology, Assiut University, Assiut, Egypt.
Hesham M HassaboDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ahmed S ShalabyDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Eman MosadDepartment of Pathology, Assiut University, Assiut, Egypt.
Kanwal RaghavDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Asif RashidDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Robert A WolffDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeffrey S MorrisDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hesham M AminDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ahmed O KasebDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphomaR01CA151533 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMIN, HESHAM M · 2011 to 2015
$1.6M
Molecular Epidemiology of Chronic Liver DiseasesK07CA106458 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HASSAN, MANAL METWALLY · 2005 to 2009
$681k
Integrating plasma IGF-1 into novel classification of hepatocellular carcinomaR21CA170035 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KASEB, AHMED · 2012 to 2013
$366k
NCI NIH HHS CA106458-01NCI NIH HHS CA170035-01NCI NIH HHS K07 CA106458NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA151533NCI NIH HHS R21 CA170035
6 · The paper itself

Abstract

backgroundThe Child-Turcotte-Pugh score (CTP) is the standard tool for hepatic reserve assessment in hepatocellular carcinoma (HCC). Recently, we reported that integrating plasma insulin-like growth factor-1 (IGF-1) level into the CTP score was associated with better patient risk stratification in two U.S. independent cohorts. Our current study aimed to validate the IGF-CTP score in patients who have different demographics and risk factors. PATIENTS AND

methodsWe prospectively recruited 100 Egyptian patients and calculated their IGF-CTP score compared to CTP score. C-index was used to compare the prognostic significance of the two scoring systems. Finally, we compared our results with our U.S. cohorts published data.

resultsIGF-CTP score showed significant better patient stratification compared to CTP score in the international validation cohort. Among CTP class A patients, who usually considered for active treatment and clinical trial enrollment, 32.5% were reclassified as IGF-CTP class B with significantly shorter OS than patients reclassified as class A with hazard ratio [HR] = 6.15, 95% confidence interval [CI] = 2.18 -17.37.

conclusionsIGF-CTP score showed significantly better patient stratification and survival prediction not only in the U.S. population but also in international validation population, who had different demographics and HCC risk factors.

Indexed as

Severity of Illness IndexAdultAgedCarcinoma, HepatocellularEgyptFemaleHumansInsulin-Like Growth Factor ILiverLiver NeoplasmsMaleMiddle AgedPrognosisProspective StudiesReproducibility of ResultsRisk FactorsIGF1 protein, humanInsulin-Like Growth Factor IChild-Pughhepatocellular carcinomaIGF-1liver reservevalidation

Identifiers

PMID26098859
PMCPMC4673259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.